Literature DB >> 1731514

Hepatic toxicity of unmodified and time-release preparations of niacin.

J I Rader1, R J Calvert, J N Hathcock.   

Abstract

Niacin (nicotinic acid) is used frequently in the treatment of hypercholesteremia. It is available in both unmodified and time-release preparations. The latter were developed in attempts to minimize the skin-flushing reaction that affects virtually all users and may limit acceptance. Adverse effects on the liver from both unmodified and time-release preparations have been recognized for many years. We reviewed the literature on the hepatic toxicity of both types of niacin preparations. Adverse reactions in six patients resulted from the exclusive use of unmodified niacin and in two patients from the exclusive use of time-release preparations. In 10 additional patients, adverse reactions developed after an abrupt change from unmodified to time-release preparations. Many of these patients were ingesting time-release niacin at doses well above the usual therapeutic doses currently recommended. Signs of liver toxicity developed in less than 7 days in four of these 10 patients. In doses that achieve equivalent reductions in serum lipids, hepatic toxicity occurred more frequently with time-release preparations than with unmodified preparations. An awareness of toxicity associated with ingestion of high doses of time-release niacin preparations is important because of their widespread availability and the potential for self-prescribed, unmonitored use.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731514     DOI: 10.1016/0002-9343(92)90018-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  Therapeutic potential of riboflavin, niacin and ascorbic acid on carbohydrate metabolizing enzymes in secondary endometrial carcinoma bearing rats.

Authors:  Sengodan Sundravel; Palanivel Shanthi; Panchanadham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2006-05-12       Impact factor: 3.396

2.  Excess vitamin intake: An unrecognized risk factor for obesity.

Authors:  Shi-Sheng Zhou; Yiming Zhou
Journal:  World J Diabetes       Date:  2014-02-15

Review 3.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols.

Authors:  M Cziraky
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 5.  Role of endothelial NAD+ deficiency in age-related vascular dysfunction.

Authors:  Anna Csiszar; Stefano Tarantini; Andriy Yabluchanskiy; Priya Balasubramanian; Tamas Kiss; Eszter Farkas; Joseph A Baur; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-15       Impact factor: 4.733

Review 6.  The benefits of niacin in atherosclerosis.

Authors:  S Tavintharan; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

Review 7.  Choosing the right lipid-regulating agent. A guide to selection.

Authors:  J A Farmer; A M Gotto
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 8.  Antihyperlipidaemic agents. Drug interactions of clinical significance.

Authors:  J A Farmer; A M Gotto
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 9.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

10.  Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.

Authors:  Barbara J Meyer; Tone Hammervold; Arild Chr Rustan; Peter R C Howe
Journal:  Lipids       Date:  2007-02-08       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.